Clin2
NCT04668872Possibly a fitRecruiting

Biopsy after liver radiation to see tumor cell changes

Colon Cancer Liver MetastasisColon CancerAdenocarcinoma of the ColonAdenocarcinoma of the RectumLiver Metastasis Colon CancerColorectal Cancer

Part of Cancer, Digestive system clinical trials.

This trial gives radiation to liver tumors and then takes a small tissue sample (biopsy) to look for changes in the cancer cells after treatment. The goal is to learn what the radiation is doing inside the tumor, which may help improve future treatments.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
80 people
Ages
18 years and older
Study type
Observational

Who can take part

  • You’re 18 years or older
  • You have colon or rectal adenocarcinoma (colon/rectum cancer subtype)
  • Your liver tumor (CLM) can’t be removed with surgery and can’t be treated with a simple needle/thermal ablation
  • You can have a biopsy of the target tumor within the last 42 days, or the study doctors recommend one at treatment time
  • Your blood and organ tests are good enough (enough white blood cells and platelets, and kidney and bilirubin levels are within limits)
  • You can’t have certain liver/radiation risk issues like prior liver radiation to the same area or severe cirrhosis/very high portal pressure

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT04491929Recruiting
Radiation treatment for colon cancer in the liver using tiny beads

This trial studies a targeted liver radiation procedure that uses tiny radioactive beads to treat colon cancer spread mostly in the liver. It may help people whose liver tumors cannot be removed or treated with other common local treatments, but it has several safety and “screening” checks.

Aarhus N, Danmark
NCT05775146Recruiting· Phase 2
Radiation to liver metastases after colon cancer treatment

This trial studies giving targeted high-dose radiation (SBRT) to liver metastases from colorectal cancer after initial treatment, with the goal of improving long-term control or cure. It may help people who have a limited number of liver spots that doctors think can be treated safely and effectively.

Edmonton, Alberta
NCT04143516Recruiting· Phase 2/Phase 3
Test tissue testing right after liver tumor ablation

This study looks at liver metastases treated with a procedure that destroys tumors (ablation) and then checks tumor tissue right away. The team wants to see whether the tissue results can guide immediate retreatment to better control cancer in the liver.

New York, New York
NCT07406126Not yet recruiting
Y-90 treatment before surgery for liver metastases

This trial tests a targeted radiation treatment (Y-90 radioembolization) given before surgery for colorectal cancer that has spread to the liver. The goal is to shrink liver tumors enough to make them removable and improve the chance of a successful surgery.

Pamplona, Navarre
NCT06257030Recruiting
Liver tumor treatment study for large tumors

This study tests a targeted radiation treatment called Y90 for liver tumors that are too large for standard approaches. It aims to see how well the treatment works for people with primary or secondary liver cancers that mainly affect the liver and have at least one tumor bigger than 5 cm.

Pátrai, Achaia
NCT06555133Recruiting· Phase 2
Study of Y-90, capecitabine, and atezolizumab for advanced colorectal cancer

This trial tests a combination of targeted radiation (Y-90), chemotherapy (capecitabine), and immunotherapy (atezolizumab) for people with colorectal cancer that has spread mainly to the liver and is no longer responding to at least two prior treatments. The goal is to see if this combination can shrink tumors or slow the disease.

Providence, Rhode Island

Hear when a new Colon Cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.